Replies to post #171461 on Biotech Values

[caravon]

The bearish argument against ABBV is that with these results they do not have a credible "natural" positioning strategy in the market

I will not sell Abbott short regarding to marketing. Abbott has an outstanding marketing expertise and capabilities. With all these numbers coming from HCV trials, the marketing will be the key.